Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today reaffirmed its strategic focus on pursuing global licensing partnerships to address the growing medical needs in the urology sector. Building upon the momentum of its recent participation at the BIO 2026 International Convention, the Company continues to actively engage in discussions with international pharmaceutical companies and industry partners across multiple regions, aiming to continuously expand its global cooperation network.

As the first company in Taiwan region to advance an oral botanical new drug to U.S. FDA Phase III clinical trials, Jyong Biotech leverages its differentiated botanical drug platform to advance presence in the global botanical drug market.

Having already established collaborative relationships with multiple international pharmaceutical companies and investment institutions, and successfully completed its first licensing cooperation agreement, the Company remains dedicated to its core strategy of innovation and global patent deployment.

A key driver of Jyong Biotech's ongoing partnership discussions is the accelerating trend of global population aging, which has made Benign Prostatic Hyperplasia (BPH) one of the most common urinary system diseases among men globally. As the prostate enlarges with age, it causes obstructive symptoms, such as a weak urinary stream, incomplete emptying, terminal dribbling, intermittency, and straining, as well as irritative symptoms like urinary frequency, urgency, and nocturia, all of which severely impact quality of life. Long-term sufferers are also prone to complications including bacterial cystitis, bladder stones, urinary retention, and renal function impairment.

According to the Global Burden of Disease (GBD 2021) and BMC Urology research, the global BPH patient population reached 112.5 million in 2021, representing an increase of over 122% from 50.7 million in 1990, and is projected to grow to between 150 million and 156 million by 2035. Correspondingly, the global BPH treatment market size is estimated at approximately $13 billion in 2025 and is expected to grow to $22 billion to $22.6 billion by 2035, growing nearly 70% over a decade. Despite this market growth, a significant unmet medical need remains due to the severe side effects and high discontinuation rates of existing treatments. Current BPH treatments primarily rely on medications such as alpha-blockers and 5-alpha reductase inhibitors (5-ARIs). However, these drugs are associated with a five-year discontinuation rate of 60% to 90% due to adverse effects like dizziness, orthostatic hypotension, ejaculatory dysfunction, and sexual dysfunction.

Jyong Biotech is focused on addressing this unmet need. Having actively engaged in discussions with international pharmaceutical companies and industry partners, the Company remains dedicated to its core strategy of innovation and global patent deployment. Additionally, the Company has conducted four Phase III clinical trials for its BPH new drug candidate, Botreso^® (API-1) in Taiwan region and the US, incorporating research from over 200 urologists. Ms. Fu-Feng Kuo, Chairwoman of Jyong Biotech, who has personally led the research team for over twenty years, stated, "The aging of the global population is an irreversible trend, and the number of BPH patients will continue to increase rapidly. We remain steadfast in our commitment to scientific evidence and innovative research, striving to provide patients with safer treatment options that are suitable for long-term use, while continuously exploring strategic avenues to introduce the independently developed botanical new drugs to the global market."

As of the date of this press release, Botreso^® remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.